ADMA Biologics develops, manufactures, and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases. The company offers IVIG products BIVIGAM and ASCENIV, as well as Nabi-HB for Hepatitis B exposure. It also develops a pipeline of plasma-derived therapeutics and operates source plasma collection facilities. Products are sold through independent distributors, wholesalers, pharmacies, and alternate site providers.
Indicator | Value |
---|---|
PER | 22.2 |
EV/EBITDA | 29.3 |
Price/Free Cash Flow' | 39.8 |
ROIC | 27.5% |
Net Debt/EBITDA | 100.0 |